<DOC>
	<DOCNO>NCT00989404</DOCNO>
	<brief_summary>The purpose study compare safety tolerability Zanamivir use Rotahaler device presentation placebo within Rotahaler presentation Diskhaler device .</brief_summary>
	<brief_title>Crossover Study Investigate Safety , Tolerability , Pharmacokinetics Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily 5 Days</brief_title>
	<detailed_description>The purpose study compare safety tolerability Zanamivir use Rotahaler placebo within Rotahaler presentation Diskhaler . Eighteen subject receive three treatment 5 day 3-way crossover design .</detailed_description>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>The subject healthy judged responsible physician clinically significant abnormality identify medical evaluation Male female volunteer 1855 year age , inclusively , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Childbearing potential agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Male subject must agree use one contraception method list protocol . Nonsmokers define abstinence cigarette smoke previous 12 month enrollment study . Body mass Index 1930 kg/m2 . FEV1 great equal 85 percent predict FEV1/FVC ratio great equal 0.7 screening . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy urine drug/ alcohol screen . Significant pulmonary disease , chronic obstructive pulmonary disease , asthma , pulmonary disease may affect pulmonary disposition study drug pose safety risk oral inhale study drug . Subjects symptoms upper respiratory infection study entry . Subjects currently present chronic upper low respiratory tract infection , allergic rhinitis , hay fever , sinusitis . Significant psychiatric disease , anxiety disorder psychotic disorder . A creatinine clearance le 70mL/min History regular alcohol consumption within 6 month study define protocol Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure four experimental medication within 12 month prior first dose day . Ingestion alcohol , grapefruit juice grapefruit product , caffeinecontaining food beverage 48 hour prior first dose study medication continue study completion . Subjects donate blood extent participation study would result excess 500mL blood donate within 56 day period . History sensitivity study medication , component thereof ( include lactose ) history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . In addition , heparin use pharmacokinetic sampling , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Those , opinion investigator , risk noncompliance study procedure . Lack suitability participation study , reason , opinion investigator . Subjects , training , unable use study related device . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pk</keyword>
	<keyword>healthy subject</keyword>
	<keyword>influenza virus</keyword>
	<keyword>Safety</keyword>
	<keyword>pandemic</keyword>
</DOC>